| Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ... Journal of Clinical Oncology 29 (34), 4548-4554, 2011 | 1242 | 2011 |
| Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma ZA Rasheed, J Yang, Q Wang, J Kowalski, I Freed, C Murter, SM Hong, ... Journal of the National Cancer Institute 102 (5), 340-351, 2010 | 532 | 2010 |
| Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations A Yang, NV Rajeshkumar, X Wang, S Yabuuchi, BM Alexander, GC Chu, ... Cancer discovery 4 (8), 905-913, 2014 | 475 | 2014 |
| A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer M Hidalgo, E Bruckheimer, NV Rajeshkumar, I Garrido-Laguna, ... Molecular cancer therapeutics 10 (8), 1311-1316, 2011 | 471 | 2011 |
| Antitumour and anticarcinogenic activity of Phyllanthus amarus extract NV Rajeshkumar, KL Joy, G Kuttan, RS Ramsewak, MG Nair, R Kuttan Journal of Ethnopharmacology 81 (1), 17-22, 2002 | 305 | 2002 |
| Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer MC Villarroel, NV Rajeshkumar, I Garrido-Laguna, A De Jesus-Acosta, ... Molecular cancer therapeutics 10 (1), 3-8, 2011 | 294 | 2011 |
| MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts NV Rajeshkumar, E De Oliveira, N Ottenhof, J Watters, D Brooks, ... Clinical cancer research 17 (9), 2799-2806, 2011 | 289 | 2011 |
| Tumor-initiating cells are rare in many human tumors K Ishizawa, ZA Rasheed, R Karisch, Q Wang, J Kowalski, E Susky, ... Cell stem cell 7 (3), 279-282, 2010 | 278 | 2010 |
| Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer I Garrido-Laguna, M Uson, NV Rajeshkumar, AC Tan, E De Oliveira, ... Clinical Cancer Research 17 (17), 5793-5800, 2011 | 275 | 2011 |
| Inhibition of chemical carcinogenesis by berberine in rats and mice KV Anis, NV Rajeshkumar, R Kuttan Journal of Pharmacy and Pharmacology 53 (5), 763-768, 2001 | 238 | 2001 |
| Characterizing DNA methylation patterns in pancreatic cancer genome AC Tan, A Jimeno, SH Lin, J Wheelhouse, F Chan, A Solomon, ... Molecular oncology 3 (5-6), 425-438, 2009 | 187 | 2009 |
| Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function NV Rajeshkumar, P Dutta, S Yabuuchi, RF De Wilde, GV Martinez, A Le, ... Cancer research 75 (16), 3355-3364, 2015 | 170 | 2015 |
| Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer S Yabuuchi, SG Pai, NR Campbell, RF De Wilde, E De Oliveira, ... Cancer letters 335 (1), 41-51, 2013 | 159 | 2013 |
| Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models G Feldmann, A Mishra, S Bisht, C Karikari, I Garrido-Laguna, Z Rasheed, ... Cancer biology & therapy 12 (7), 598-609, 2011 | 143 | 2011 |
| Phyllanthus amarus extract administration increases the life span of rats with hepatocellular carcinoma NV Rajeshkumar, R Kuttan Journal of ethnopharmacology 73 (1-2), 215-219, 2000 | 137 | 2000 |
| Small-molecule inhibition of Axl targets tumor immune suppression and enhances chemotherapy in pancreatic cancer KF Ludwig, W Du, NB Sorrelle, K Wnuk-Lipinska, M Topalovski, ... Cancer research 78 (1), 246-255, 2018 | 136 | 2018 |
| Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma A De Jesus-Acosta, EA Sugar, PJ O’Dwyer, RK Ramanathan, ... British journal of cancer 122 (4), 498-505, 2020 | 127 | 2020 |
| Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth ML Fishel, Y Jiang, NV Rajeshkumar, G Scandura, AL Sinn, Y He, C Shen, ... Molecular cancer therapeutics 10 (9), 1698-1708, 2011 | 125 | 2011 |
| Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer A Jimeno, AC Tan, J Coffa, NV Rajeshkumar, P Kulesza, ... Cancer research 68 (8), 2841-2849, 2008 | 122 | 2008 |
| Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer D Laheru, P Shah, NV Rajeshkumar, F McAllister, G Taylor, H Goldsweig, ... Investigational new drugs 30 (6), 2391-2399, 2012 | 119 | 2012 |
ANIRBAN MAITRAProfessor of Translational Molecular Pathology, UT MD Anderson Cancer Center在 mdanderson.org 的电子邮件经过验证
